---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: a4d63129f53cd022667129fa13e8984e7045ea297b25fd6e9409b7b4c5898de2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and vanity metrics (usage percentages) are being driven by incentives—bundle pricing for sales and "sample auditing" by managers—rather than core product value.

The most dangerous signal in your data is the behavior of front-line adjusters: they use the tool for 48 hours and then revert to manual notes. This suggests DraftPath is perceived as a "novelty" or a "compliance checkbox" rather than a utility. If you scale now, you are scaling a feature that adjusters find untrustworthy or cumbersome.

Here is why the other options are inferior in this specific window:
*   **Scaling Broadly:** This is high-risk. You have early warnings of churn from regional carriers and a fundamental "explainability" failure in the health-liability segment. Scaling a flawed workflow creates technical and reputational debt.
*   **Usage Quality Sprint:** This is "more of the same" quantitative data. You already know *that* they aren't returning; you don't know *why*. Tracking the decline in real-time doesn't fix the product.
*   **Commercial Cleanroom:** This is a sales experiment, not a product one. While it would prove if the bundle pricing is masking a lack of value, it doesn't tell you how to fix DraftPath. It tells you if the product is sellable, not if it is usable.
*   **Narrowing to Health-Liability:** This is a premature pivot. You have evidence that it's failing there, but you don't yet know if it's a universal failure of the logic or a specific regulatory hurdle.

**The Claim File Review is the only option that addresses the "Ground Truth."** By auditing actual files, you move past what users *say* in sales calls and what the *dashboard says* about clicks. You will see exactly where the "manual rewrite" happens. This allows you to determine if DraftPath is providing a 10% lift (worth scaling) or a 0% lift that requires 20% more effort to verify (a liability).

### The Modification
I recommend modifying the Claim File Review to include a **"Regulatory Gap Analysis."** This displaces the general "Claim File Review" by specifically requiring a subset of files from the health-liability segment to be reviewed alongside their internal compliance checklists.
*   **What you give up:** You sacrifice a broader, random sample of all account types to spend more time on the high-friction health-liability segment.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, qualitative, and "unscalable." While the board wants a budget for next year, this review provides anecdotal evidence rather than a clean spreadsheet of ROI. There is a risk that the CEO will find the results too "small-sample" to justify a major strategic shift, whereas the Commercial Cleanroom provides hard revenue numbers that executives typically prefer.

### The Evidence That Would Change My Mind
If the **regional carriers** who plan to remove DraftPath provide specific, documented feedback that their adjusters *love* the tool but the *procurement/legal* teams are blocking it due to pricing or contract terms, I would pivot to the **Commercial Cleanroom**.

If the friction is purely financial/contractual, you have a pricing problem. But if the friction is "the adjusters stopped using it after two days," you have a product problem—and only the Claim File Review can diagnose that.
